{"disease":{"id":"advanced-hodgkin-lymphoma","name":"advanced hodgkin lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03188965","title":"First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":229,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06857500","title":"Brentuximab Vedotin with Adriamycin, Vinblastine and Dacarbazine for Patients Aged 18-59 Years with Untreated Advanced-stage Classical Hodgkin Lymphoma: a Real-life Experience","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Federico II University","has_results":false},{"nct_id":"NCT03013218","title":"A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"ALX Oncology Inc.","has_results":false},{"nct_id":"NCT01655225","title":"A Study of LY3023414 in Participants With Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT03517137","title":"Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":true},{"nct_id":"NCT06745076","title":"Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":125,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT06223542","title":"Studying TAK-243 in Patients With Advanced Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":95,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04772989","title":"A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Arcus Biosciences, Inc.","has_results":false},{"nct_id":"NCT07410494","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT06028373","title":"A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Antengene Biologics Limited","has_results":false},{"nct_id":"NCT05892718","title":"A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"FBD Biologics Limited","has_results":false},{"nct_id":"NCT02408861","title":"Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03657381","title":"Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":75,"lead_sponsor_name":"Shandong New Time Pharmaceutical Co., LTD","has_results":false},{"nct_id":"NCT07171827","title":"Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Helwan University","has_results":false},{"nct_id":"NCT02595866","title":"Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02875548","title":"A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Epizyme, Inc.","has_results":false},{"nct_id":"NCT05880043","title":"GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"GI Cell, Inc.","has_results":false},{"nct_id":"NCT06487624","title":"An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"FBD Biologics Limited","has_results":false},{"nct_id":"NCT07002216","title":"BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT04537715","title":"Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Epizyme, Inc.","has_results":true},{"nct_id":"NCT05564806","title":"Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":38,"lead_sponsor_name":"Eucure (Beijing) Biopharma Co., Ltd","has_results":false},{"nct_id":"NCT05490043","title":"A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":33,"lead_sponsor_name":"Antengene (Hangzhou) Biologics Co., Ltd.","has_results":false},{"nct_id":"NCT04986865","title":"A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Antengene Biologics Limited","has_results":false},{"nct_id":"NCT05678998","title":"WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Werewolf Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03526250","title":"Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02520791","title":"Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03213691","title":"Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03698994","title":"Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03210714","title":"Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03213665","title":"Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03027284","title":"A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT05714553","title":"NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"NuCana plc","has_results":false},{"nct_id":"NCT03213678","title":"Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03061188","title":"Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Northwestern University","has_results":true},{"nct_id":"NCT03213652","title":"Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03213704","title":"Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05144334","title":"A Study of BTX-1188 in Subjects With Advanced Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Biotheryx, Inc.","has_results":false},{"nct_id":"NCT03233204","title":"Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03220035","title":"Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03878524","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT03925428","title":"Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":42},"guidelines":[],"source":"Drug Landscape verified database"}